Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Up – Here’s What Happened

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) gapped up before the market opened on Wednesday . The stock had previously closed at $25.94, but opened at $27.6599. Chugai Pharmaceutical shares last traded at $26.62, with a volume of 5,376 shares.

Analyst Upgrades and Downgrades

CHGCY has been the topic of a number of research reports. UBS Group raised shares of Chugai Pharmaceutical to a “strong-buy” rating in a research note on Tuesday, January 27th. Smbc Nikko Sec. upgraded shares of Chugai Pharmaceutical to a “strong-buy” rating in a report on Wednesday, February 25th. Two analysts have rated the stock with a Strong Buy rating, According to MarketBeat, the company presently has an average rating of “Strong Buy”.

Chugai Pharmaceutical Trading Up 2.2%

The stock’s 50 day moving average price is $29.14 and its 200 day moving average price is $26.38. The company has a market capitalization of $87.21 billion, a price-to-earnings ratio of 30.46 and a beta of 0.60.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings results on Thursday, January 29th. The company reported $0.25 EPS for the quarter. The firm had revenue of $2.25 billion during the quarter. Chugai Pharmaceutical had a return on equity of 22.00% and a net margin of 34.47%. On average, research analysts expect that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.